Phaseline

Companies › Exelixis

Exelixis: clinical trials, targets and expected readouts

6 active drug programs in 78 registered trials: 42 Phase 2, 23 Phase 1, 10 Phase 3, 3 Phase 4; Oncology, Gastroenterology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cabozantinib (XL184)
Vascular endothelial growth factor receptor 2 inhibitor; Hepatocyte growth factor receptor inhibitor
KDR, METPhase 4Medullary Thyroid Cancer; Hepatocellular Carcinoma; Metastatic Prostate Cancer; Renal Cell Carcinoma …Jan 2027
Zanzalintinib (XL092)
Multi-targeted tyrosine kinase inhibitor targeting FGFR, MET, ROS1, and AXL
FGFR1, FGFR2, FGFR3, FGFR4, MET, KIT, PDGFRAPhase 3Non-Clear Cell Renal Cell Carcinoma; Colorectal Cancer; Meningioma; Head and Neck Squamous Cell Carcinoma …Dec 2026
XB010–Phase 1Locally Advanced or Metastatic Solid TumorsNov 2026
XL309 (ISM3091)
ATM inhibitor
ATMPhase 1Advanced Solid TumorApr 2027
XB628–Phase 1Solid TumorMay 2027
XB371–Phase 1Solid TumorsNov 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03755791Cabozantinib (XL184)Phase 3Hepatocellular CarcinomaOncologyNov 2021
NCT04446117Cabozantinib (XL184)Phase 3Metastatic Prostate CancerOncologyApr 2024
NCT04289779Cabozantinib (XL184)Phase 2Bladder CancerOncologyJun 2025
NCT06962332Zanzalintinib (XL092)Phase 1Hepatic ImpairmentGastroenterologyDec 2025
NCT04204850Cabozantinib (XL184)Phase 2Hepatocellular CarcinomaOncologyJun 2026
NCT05502315Cabozantinib (XL184)Phase 2Castration-resistant Prostate CancerOncologyNov 2026
NCT06545331XB010Phase 1Locally Advanced or Metastatic Solid TumorsOncologyNov 2026
NCT05425004Cabozantinib (XL184)Phase 2MeningiomaOncologyDec 2026
NCT05263050Cabozantinib (XL184)Phase 2Metastatic Renal Cell CarcinomaOncologyDec 2026
NCT04091750Cabozantinib (XL184)Phase 2MelanomaOncologyDec 2026
NCT04893785Cabozantinib (XL184)Phase 2Lung Neuroendocrine NeoplasmOncologyDec 2026
NCT05182164Cabozantinib (XL184)Phase 2Soft Tissue Sarcoma AdultOncologyDec 2026
NCT05678673Zanzalintinib (XL092)Phase 3Non-Clear Cell Renal Cell CarcinomaOncologyDec 2026
NCT04413123Cabozantinib (XL184)Phase 2Papillary Renal Cell CarcinomaOncologyDec 2026
NCT05168163Cabozantinib (XL184)Phase 2Locally Advanced Hepatocellular CarcinomaOncologyDec 2026
NCT06698250Zanzalintinib (XL092)Phase 2Hepatocellular CarcinomaOncologyDec 2026
NCT03937219Cabozantinib (XL184)Phase 3Renal Cell CarcinomaOncologyJan 2027
NCT04472767Cabozantinib (XL184)Phase 2Hepatocellular CarcinomaOncologyJan 2027
NCT05425940Zanzalintinib (XL092)Phase 3Colorectal CancerOncologyJan 2027
NCT05176483Zanzalintinib (XL092)Phase 1Renal Cell Carcinoma (RCC)OncologyJan 2027
NCT04551430Cabozantinib (XL184)Phase 2Metastatic Soft-tissue SarcomaOncologyFeb 2027
NCT04963283Cabozantinib (XL184)Phase 2Colorectal AdenocarcinomaOncologyFeb 2027
NCT06835972Cabozantinib (XL184)Phase 1Metastatic Renal Cell CarcinomaOncologyFeb 2027
NCT04412629Cabozantinib (XL184)Phase 2High Grade Neuroendocrine NeoplasmsOncologyMar 2027
NCT05559879Cabozantinib (XL184)Phase 1Gynecologic CancerOncologyApr 2027
NCT05932862XL309 (ISM3091)Phase 1Advanced Solid TumorOncologyApr 2027
NCT04322955Cabozantinib (XL184)Phase 2Kidney CancerOncologyMay 2027
NCT06952010Zanzalintinib (XL092)Phase 1Solid TumorOncologyMay 2027
NCT03845166Zanzalintinib (XL092)Phase 1Neoplasm MalignantOncologyMay 2027
NCT06952010XB628Phase 1Solid TumorOncologyMay 2027
NCT06912087Zanzalintinib (XL092)Phase 1Head and Neck NeoplasmsOncologyJun 2027
NCT01639508Cabozantinib (XL184)Phase 2Non-Small Cell Lung CancerOncologyJul 2027
NCT03690388Cabozantinib (XL184)Phase 3Differentiated Thyroid CancerOncologyJul 2027
NCT04200443Cabozantinib (XL184)Phase 2Metastatic LeiomyosarcomaOncologyAug 2027
NCT03635892Cabozantinib (XL184)Phase 2Advanced or Metastatic Non-clear Cell Renal Cell CarcinomaOncologyAug 2027
NCT05048901Cabozantinib (XL184)Phase 1Neuroendocrine Tumors,GastroenteropancreaticGastroenterologyAug 2027
NCT05931393Cabozantinib (XL184)Phase 2RCCOncologySep 2027
NCT07077161Cabozantinib (XL184)Phase 2Renal Cell Carcinoma (RCC)OncologySep 2027
NCT03170960Cabozantinib (XL184)Phase 1Urothelial CarcinomaOncologySep 2027
NCT05361720Cabozantinib (XL184)Phase 2Advanced Clear Cell Renal Cell CarcinomaOncologyOct 2027
NCT04116541Cabozantinib (XL184)Phase 2Malignant Solid TumorOncologyOct 2027
NCT06156410Cabozantinib (XL184)Phase 1Ewing SarcomaOncologyNov 2027
NCT06132945Cabozantinib (XL184)Phase 1Metastatic Renal Cell CarcinomaOncologyNov 2027
NCT07123103XB371Phase 1Solid TumorsOncologyNov 2027
NCT05127824Cabozantinib (XL184)Phase 2Carcinoma, Renal CellOncologyDec 2027
NCT05249114Cabozantinib (XL184)Phase 1Neuroendocrine TumorsOncologyDec 2027
NCT04588051Cabozantinib (XL184)Phase 2HCCOncologyDec 2027
NCT07428616Zanzalintinib (XL092)Phase 2MeningiomaOncologyFeb 2028
NCT06959511Zanzalintinib (XL092)Phase 2Neoadjuvant TreatmentOncologyMar 2028
NCT06934057Cabozantinib (XL184)Phase 4Kidney CancerOncologyApr 2028
NCT05836571Cabozantinib (XL184)Phase 2Locally Advanced Extraskeletal Myxoid ChondrosarcomaOncologyMay 2028
NCT06794229Zanzalintinib (XL092)Phase 2Locally Advanced Renal Cell CarcinomaOncologyJun 2028
NCT05327686Cabozantinib (XL184)Phase 2Metastatic Renal Cell CarcinomaOncologyJun 2028
NCT03539822Cabozantinib (XL184)Phase 1Gastric CancerOncologyJun 2028
NCT06571734Zanzalintinib (XL092)Phase 2Metastatic LeiomyosarcomaOncologyJul 2028
NCT07218666Zanzalintinib (XL092)Phase 2Aggressive Variant Prostate CarcinomaOncologyJul 2028
NCT06082167Zanzalintinib (XL092)Phase 2Head and Neck Squamous Cell CarcinomaOncologyAug 2028
NCT06959641Zanzalintinib (XL092)Phase 2Locally Advanced Differentiated Thyroid Gland CarcinomaOncologySep 2028
NCT05613413Cabozantinib (XL184)Phase 2Metastatic Squamous Non-Small Cell Lung CarcinomaOncologySep 2028
NCT07028125Cabozantinib (XL184)Phase 4Renal Cell Carcinoma (Kidney Cancer)OncologyOct 2028

The 60 nearest readouts of 78 trials; the rest in the app.

From the company's SEC filings

Cash and short-term investments of $892m on 2026-10-02; operating cash flow positive

Press releases filed as 8-K in the last year:

Specialist investors

Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

MET (2) KDR (1) FGFR1 (1) FGFR2 (1) FGFR3 (1) FGFR4 (1) KIT (1) PDGFRA (1) ATM (1)

Companies with the same targets

AstraZeneca Tyra Biosciences Johnson & Johnson (Janssen) Hutchmed Taiho Oncology QED Therapeutics, a BridgeBio company TransThera Sciences (Nanjing) Chia Tai Tianqing Pharmaceutical Group Eli Lilly Eisai

Companies built like this

Genmab Immunocore Hutchmed Nurix Therapeutics Jazz Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.